← All trials
NCT05188664
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2022
- Primary completion
- Oct 1, 2023
- Completion date
- Mar 1, 2024
- First posted
- Jan 12, 2022
- Last posted
- May 23, 2022
- Enrollment
- 50
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- LaNova Medicines LimitedLead sponsor
- Chris O'Brien LifehouseOverall official - principal investigator
- Macquarie UniversityOverall official - principal investigator
- Peninsula & South Eastern Haematology & Oncology GroupOverall official - principal investigator
- Monash UniversityOverall official - principal investigator
- Chris O'Brien LifehouseOfficial
- Peninsula & South Eastern Haematology & Oncology GroupOfficial
- Macquarie UniversityOfficial
- Monash UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.